Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.

424B3 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Coeptis Therapeutics Holdings (COEP US)

424B3 | Prospectus

424B3 | Prospectus

Quarterly Report (Amendment) (Form 10-Q/A | Period ending 2023-09-30)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Annual Report (Amendment) (Form 10-K/A | Period ending 2023-12-31)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)